Skip to main content
Premium Trial:

Request an Annual Quote

Rosetta Genomics Sells 560,000 Additional Shares in IPO Over-Allotment

NEW YORK (GenomeWeb News) — Underwriters taking part in Rosetta Genomics’ initial public offering last month bought 562,000 additional shares as part of an over-allotment.
.
The over-allotment makes the total IPO’s net value $26.2 million on 4.3 million shares sold, after the initial sale of 3.75 million shares at $7 a share.
 
Rosetta’s stock was down 2.4 percent at $8.15 in early-afternoon trading today.
The Scan

Lung Cancer Response to Checkpoint Inhibitors Reflected in Circulating Tumor DNA

In non-small cell lung cancer patients, researchers find in JCO Precision Oncology that survival benefits after immune checkpoint blockade coincide with a dip in ctDNA levels.

Study Reviews Family, Provider Responses to Rapid Whole-Genome Sequencing Follow-up

Investigators identified in the European Journal of Human Genetics variable follow-up practices after rapid whole-genome sequencing.

BMI-Related Variants Show Age-Related Stability in UK Biobank Participants

Researchers followed body mass index variant stability with genomic structural equation modeling and genome-wide association studies of 40- to 72-year olds in PLOS Genetics.

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.